A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma

Table 2

Overview of trial patient baseline characteristics.

Potential matching variable	Available and presented consistently in BOLT and ERIVANCE?	Distribution differs between BOLT and ERIVANCE?	Is the variable prognostic?
Age	Yes	No; (i) BOLT = 64.6 (mean); (ii) ERIVANCE = 61.4 (mean)	BOLT exploratory analysis suggests prognostic [7], but Chang et al. [25] suggest nonsignificant relationship with ORR
Sex	Yes	No; (i) BOLT = 57.6% (male); (ii) ERIVANCE = 55.6% (male)	Unknown
Race	Yes	No; (i) BOLT = 89.4% white, 10.6% other; (ii) ERIVANCE = 100% white	Unknown
ECOG status	Yes	No; (i) BOLT: (a) ECOG status 0 = 66.7%; (b) ECOG status 1 = 24.2%; (c) ECOG status 2 = 6.1%; (ii) ERIVANCE; (a) ECOG status 0 = 76.2%; (b) ECOG status 1 = 20.6%; (c) ECOG status 2 = 3.2%	BOLT exploratory analysis suggests prognostic [7]
Prior radiotherapy for BCC	Yes	Yes; (i) BOLT = 7.6%; (ii) ERIVANCE = 20.6% for target and 27.0% for current or prior	Chang et al. [25] suggest nonsignificant relationship with ORR
Prior systemic therapy for BCC	Yes	No; (i) BOLT = 6.1%; (ii) ERIVANCE = 11.1% (systematic or topical)	Chang et al. [25] suggest significant relationship with ORR
Prior surgery for BCC	Yes	Yes; (i) BOLT = 72.7%; (ii) ERIVANCE = 88.9%	Clinical advisors suggest highly prognostic in refractory population

BCC: basal cell carcinoma; ECOG: Eastern Cooperative Oncology Group; ORR: objective response rate. Note. BOLT summaries are based on the 200 mg full analysis set population [7]; ERIVANCE summaries are based on Sekulic et al. [8] and the European Medicines Agency assessment report [9].